Vildagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i), is used to treat type 2 diabetes mellitus (DM2) because it increases the concentrations of incretins, which stimulate the release of insulin and reduce glucagon secretion in a glucose-dependent manner. Here, DPP4 is linked to diabetes mellitus.